After administration of mobilizing regimens ( primarily high-dose etoposide , high-dose cyclophosphamide , intermediate-dose Ara-C or ESHAP ) , patients were randomized to a standard daily 10 g/kg dose of biosimilar G-CSF ( n = 54 ) or originator G-CSF ( n = 54 ) .